Grant: Master's Award: Canada Graduate Scholarships
University of British Columbia
$17,500.00
Development of an Oncofetal Chondroitin Sulfate Targeting Immunocytokine
FY 2023-24
Summary
The survival probability of children diagnosed with metastatic sarcomas is dismal and alternative treatment options are needed. Oncofetal chondroitin sulfate (ofCS) is a long and highly sulfated sugar chain that protrudes from the outer membrane of cancer cells. Normally, ofCS is present exclusively in the placenta where it facilitates correct placental invasion and implementation in the uterine tissue during pregnancy. Solid tumors, including pediatric sarcomas, mimic the placental functionality of ofCS to establish invasive and metastatic properties of the cancer cells. The oncofetal expression and malignant functionality of ofCS makes it an attractive target for cancer therapy. Our team has developed a panel of first-in-class antibodies with unique specificity and binding strength to ofCS. In this master project, I will test two bispecific immunocytokines comprised of ofCS antibodies fused to a potent human immune cell stimulating cytokine called interleukin 2 (IL-2). IL-2 is already approved for the treatment of various advanced cancers, but its clinical utility is limited due to its severe systemic side-effects when given intravenously. My hypothesis is that targeting IL-2 to ofCS in the tumors will improve its clinical applicability. I aim to (1) examine and validate the binding specificity and functionality of the bispecific immunocytokines; and (2) test the anti-cancer efficacy in 2D and 3D model systems of human sarcoma cells and immune cells. My project combines fundamental glycobiology with immunology and translational cancer research. With this approach, we hope to improve the utility of IL-2 immunotherapy and contribute to development of viable therapeutics targeting the sugar coat of pediatric sarcomas and potentially other malignancies.
Department
Program
Master's Award: Canada Graduate Scholarships
Recipient
Location
British Columbia, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
506329
Name
Varghese Sarah
Region
British Columbia
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Development of an Oncofetal Chondroitin Sulfate Targeting Immunocytokine
Programtype2
Studentship Programs
Orgnameinp2
University of British Columbia
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Ewing Sarcoma; Glycobiology; Immunocytokines; Immunotherapy; Oncofetal Chondroitin Sulfate; Osteosarcoma; Paediatric Cancer; Protein Construct; Targeted Therapy; Translational Cancer Research
Abstract
The survival probability of children diagnosed with metastatic sarcomas is dismal and alternative treatment options are needed. Oncofetal chondroitin sulfate (ofCS) is a long and highly sulfated sugar chain that protrudes from the outer membrane of cancer cells. Normally, ofCS is present exclusively in the placenta where it facilitates correct placental invasion and implementation in the uterine tissue during pregnancy. Solid tumors, including pediatric sarcomas, mimic the placental functionality of ofCS to establish invasive and metastatic properties of the cancer cells. The oncofetal expression and malignant functionality of ofCS makes it an attractive target for cancer therapy. Our team has developed a panel of first-in-class antibodies with unique specificity and binding strength to ofCS. In this master project, I will test two bispecific immunocytokines comprised of ofCS antibodies fused to a potent human immune cell stimulating cytokine called interleukin 2 (IL-2). IL-2 is already approved for the treatment of various advanced cancers, but its clinical utility is limited due to its severe systemic side-effects when given intravenously. My hypothesis is that targeting IL-2 to ofCS in the tumors will improve its clinical applicability. I aim to (1) examine and validate the binding specificity and functionality of the bispecific immunocytokines; and (2) test the anti-cancer efficacy in 2D and 3D model systems of human sarcoma cells and immune cells. My project combines fundamental glycobiology with immunology and translational cancer research. With this approach, we hope to improve the utility of IL-2 immunotherapy and contribute to development of viable therapeutics targeting the sugar coat of pediatric sarcomas and potentially other malignancies.
Competitiondate
202312
Approvedterm2
1 yr 0 mth
Pinamesdelim
Varghese, Sarah
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~